Understanding Transglutaminase 2's Role in Celiac Disease
Official title: Localizing Pathogenically Relevant Transglutaminase 2 in Celiac Disease
Funded at Stanford University · NIH-11145816 · Data updated 2026-11-12
This work explores how a specific enzyme, Transglutaminase 2 (TG2), contributes to celiac disease in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 7, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $351,340 |
| NIH project number | 5R01DK126487-05 |
| Project ID | NIH-11145816 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research is for patients with celiac disease who are interested in understanding the underlying causes of their condition and future treatment possibilities.
✕Less likely to help
Patients seeking immediate new treatments or direct clinical trial participation would not directly benefit from this early-stage laboratory research.
What this research studies
Celiac disease is an inflammatory condition of the small intestine caused by gluten, and currently, the only treatment is a strict gluten-free diet. This project aims to discover where TG2, an enzyme central to celiac disease, acts in the body to cause harm. We believe that TG2 found in the intestine reacts with gluten, leading to the formation of autoantibodies that are a hallmark of the disease. By understanding this process, we hope to uncover new ways to help people with celiac disease.
Why it matters
Potential benefit: If successful, this work could lead to new non-dietary treatments for celiac disease by targeting the specific actions of the TG2 enzyme.
How similar studies have gone: While the role of TG2 in celiac disease is known, this specific hypothesis about its location and mechanism of action is novel and currently untested.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Khosla, Chaitan — Stanford University
- Study coordinator: Khosla, Chaitan
Related research
Other NIH-funded projects on the same topics.
-
Understanding how immune cells interact in celiac disease to guide healing
A study from the University of Chicago will follow people with celiac disease to understand how immune cells in the gut contribute to damage or healing when gluten is present or restricted.
-
NanoDiscs: a new way to calm the immune system in celiac disease
A new, protein-like particle called NanoDiscs is being developed to deliver safe targets to the immune system in people with celiac disease, with the goal of reducing reactions to gluten.
-
Tissue damage and healing in Celiac Disease
A broad study at the University of Chicago is exploring why some people with celiac disease keep having symptoms and tissue damage even when they try to follow a gluten-free diet.
-
Gluten-detection devices and telemedicine to help adults with celiac disease
This project looks at whether using portable gluten sensors and urine gluten tests together with telemedicine can help adults with celiac disease stick to a gluten-free diet and feel better.
-
Gluten-sensing tech to help manage celiac disease with telemedicine
A study tests new gluten-detection tools used with online care to help adults with celiac disease manage their condition.
-
Role of Transglutaminase 2 in Celiac Disease
A study from Stanford aims to understand how a specific enzyme, TG2, contributes to celiac disease and to test a potential gut-focused treatment that could one day help people avoid dietary controls.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.